Skip to main content
Erschienen in: Journal of Neurology 6/2016

25.04.2016 | Original Communication

Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes

verfasst von: H. A. Jinnah, Emily Goodmann, Ami R. Rosen, Marian Evatt, Alan Freeman, Stewart Factor

Erschienen in: Journal of Neurology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Botulinum toxin (BoNT) is highly effective in the treatment of cervical dystonia (CD), yet a significant proportion of patients report low levels of satisfaction following treatment and fail to follow up for repeated treatments. The goal of this study was to determine the reasons that some patients have unsatisfactory responses. A total of 35 subjects who came to our center requesting alternative treatments due to unsatisfactory responses following BoNT treatment for CD were evaluated. Included were 26 women and 9 men with an average age of 57.1 years (range 25–82 years), and an average duration of illness of 12.5 years (range 1–55 years). Details of unsatisfactory BoNT treatments were methodically collected by a movement specialist using a standardized intake form, including provider subspecialty, product used, the number of satisfactory or unsatisfactory trials, doses given, specific muscles treated, the use of electromyographic guidance, side effects, and tests of resistance. The specialist then provided repeat treatments if indicated, and followed each case until the reasons for unsatisfactory outcomes could be determined. Multiple reasons for unsatisfactory outcomes were found. They included suboptimal BoNT doses, suboptimal muscle targeting, intolerable side effects, complex movement patterns, discordant perceptions, and incorrect diagnoses. Only one patient was functionally resistant to BoNT. Of 32 subjects who received repeat BoNT treatments, 25 (78 %) achieved satisfactory responses after revision of the original treatment plan. These results indicate that the majority of unsatisfactory responses to BoNT treatment of CD were caused by correctible factors and imply a need for improved education regarding optimal treatment methods.
Literatur
1.
Zurück zum Zitat Jinnah HA, Factor S (2015) Diagnosis and treatment of dystonia. In: Jankovic J (ed) Neurologic clinics. Elsevier, Amsterdam, pp 77–100 Jinnah HA, Factor S (2015) Diagnosis and treatment of dystonia. In: Jankovic J (ed) Neurologic clinics. Elsevier, Amsterdam, pp 77–100
2.
3.
Zurück zum Zitat Hallett M, Albanese A, Dressler D et al (2013) Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon 67:94–114CrossRefPubMed Hallett M, Albanese A, Dressler D et al (2013) Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon 67:94–114CrossRefPubMed
4.
Zurück zum Zitat Albanese A, Abbruzzese G, Dressler D et al (2015) Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. J Neurol 262:2201–2213CrossRefPubMedPubMedCentral Albanese A, Abbruzzese G, Dressler D et al (2015) Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. J Neurol 262:2201–2213CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Sethi KD, Rodriguez R, Olayinka B (2012) Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J Med Econ 15:419–423CrossRefPubMed Sethi KD, Rodriguez R, Olayinka B (2012) Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J Med Econ 15:419–423CrossRefPubMed
6.
Zurück zum Zitat Skogseid IM, Kerty E (2005) The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment. Eur J Neurol 12:163–170CrossRefPubMed Skogseid IM, Kerty E (2005) The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment. Eur J Neurol 12:163–170CrossRefPubMed
8.
Zurück zum Zitat Jankovic J, Adler CH, Charles D et al (2015) Primary results from the cervical dystonia patient registry for observation of OnabotulinumtoxinA efficacy (CD PROBE). J Neurol Sci 349:84–93CrossRefPubMed Jankovic J, Adler CH, Charles D et al (2015) Primary results from the cervical dystonia patient registry for observation of OnabotulinumtoxinA efficacy (CD PROBE). J Neurol Sci 349:84–93CrossRefPubMed
9.
Zurück zum Zitat Evidente VG, Pappert EJ (2014) Botulinum toxin therapy for cervical dystonia: the science of dosing. Tremor Other Hyperkinet Mov 4:273 Evidente VG, Pappert EJ (2014) Botulinum toxin therapy for cervical dystonia: the science of dosing. Tremor Other Hyperkinet Mov 4:273
10.
Zurück zum Zitat Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O (2002) Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 17:1288–1293CrossRefPubMed Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O (2002) Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 17:1288–1293CrossRefPubMed
11.
Zurück zum Zitat Nijmeijer SW, Koelman JH, Standaar TS, Postma M, Tijssen MA (2013) Cervical dystonia: improved treatment response to botulinum toxin after referral to a tertiary centre and the use of polymyography. Parkinsonism Relat Disord 19:533–538CrossRefPubMed Nijmeijer SW, Koelman JH, Standaar TS, Postma M, Tijssen MA (2013) Cervical dystonia: improved treatment response to botulinum toxin after referral to a tertiary centre and the use of polymyography. Parkinsonism Relat Disord 19:533–538CrossRefPubMed
12.
Zurück zum Zitat Brashear A, Bergan K, Wojcieszek J, Siemers ER, Ambrosius W (2000) Patients’ perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A. Mov Disord 15:150–153CrossRefPubMed Brashear A, Bergan K, Wojcieszek J, Siemers ER, Ambrosius W (2000) Patients’ perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A. Mov Disord 15:150–153CrossRefPubMed
13.
Zurück zum Zitat Gill CE, Manus ND, Pelster MW et al (2013) Continuation of long-term care for cervical dystonia at an academic movement disorders clinic. Toxins (Basel) 5:776–783CrossRef Gill CE, Manus ND, Pelster MW et al (2013) Continuation of long-term care for cervical dystonia at an academic movement disorders clinic. Toxins (Basel) 5:776–783CrossRef
14.
15.
Zurück zum Zitat Brin MF, Comella CL, Jankovic J, Lai F, Naumann M (2008) Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 23:1353–1360CrossRefPubMed Brin MF, Comella CL, Jankovic J, Lai F, Naumann M (2008) Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 23:1353–1360CrossRefPubMed
16.
Zurück zum Zitat Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K (2009) Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol 32:213–218CrossRefPubMed Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K (2009) Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol 32:213–218CrossRefPubMed
17.
Zurück zum Zitat Ferreira JJ, Colosimo C, Bhidayasiri R, Marti MJ, Maisonobe P, Om S (2015) Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia. Parkinsonism Relat Disord 21:111–115CrossRefPubMed Ferreira JJ, Colosimo C, Bhidayasiri R, Marti MJ, Maisonobe P, Om S (2015) Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia. Parkinsonism Relat Disord 21:111–115CrossRefPubMed
18.
Zurück zum Zitat Ferreira JJ, Bhidayasiri R, Colosimo C, Marti MJ, Zakine B, Maisonobe P (2012) Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia. Funct Neurol 27:225–230PubMedPubMedCentral Ferreira JJ, Bhidayasiri R, Colosimo C, Marti MJ, Zakine B, Maisonobe P (2012) Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia. Funct Neurol 27:225–230PubMedPubMedCentral
20.
Zurück zum Zitat Coleman C, Hubble J, Schwab J, Beffy JL, Picaut P, Morte C (2012) Immunoresistance in cervical dystonia patients after treatment with abobotulinumtoxinA. Int J Neurosci 122:358–362CrossRefPubMed Coleman C, Hubble J, Schwab J, Beffy JL, Picaut P, Morte C (2012) Immunoresistance in cervical dystonia patients after treatment with abobotulinumtoxinA. Int J Neurosci 122:358–362CrossRefPubMed
21.
Zurück zum Zitat Ruiz PJ, Castrillo JC, Burguera JA et al (2011) Evolution of dose and response to botulinum toxin A in cervical dystonia: a multicenter study. J Neurol 258:1055–1057CrossRefPubMed Ruiz PJ, Castrillo JC, Burguera JA et al (2011) Evolution of dose and response to botulinum toxin A in cervical dystonia: a multicenter study. J Neurol 258:1055–1057CrossRefPubMed
22.
Zurück zum Zitat Fabbri M, Leodori G, Fernandes RM et al (2015) Neutralizing antibody and Botulinum toxin therapy: A systematic review and meta-analysis. Neurotox Res (in press) Fabbri M, Leodori G, Fernandes RM et al (2015) Neutralizing antibody and Botulinum toxin therapy: A systematic review and meta-analysis. Neurotox Res (in press)
23.
Zurück zum Zitat Svetel M, Pekmezovic T, Tomic A, Kresojevic N, Kostic VS (2015) The spread of primary late-onset focal dystonia in a long-term follow up study. Clin Neurol Neurosurg 132:41–43CrossRefPubMed Svetel M, Pekmezovic T, Tomic A, Kresojevic N, Kostic VS (2015) The spread of primary late-onset focal dystonia in a long-term follow up study. Clin Neurol Neurosurg 132:41–43CrossRefPubMed
24.
Zurück zum Zitat Jahanshahi M, Marion MH, Marsden CD (1990) Natural history of adult-onset idiopathic torticollis. Arch Neurol 47:548–552CrossRefPubMed Jahanshahi M, Marion MH, Marsden CD (1990) Natural history of adult-onset idiopathic torticollis. Arch Neurol 47:548–552CrossRefPubMed
25.
Zurück zum Zitat Martino D, Berardelli A, Abbruzzese G et al (2012) Age at onset and symptom spread in primary adult-onset blepharospasm and cervical dystonia. Mov Disord 27:1447–1450CrossRefPubMed Martino D, Berardelli A, Abbruzzese G et al (2012) Age at onset and symptom spread in primary adult-onset blepharospasm and cervical dystonia. Mov Disord 27:1447–1450CrossRefPubMed
26.
Zurück zum Zitat Svetel M, Pekmezovic T, Jovic J et al (2007) Spread of primary dystonia in relation to initially affected region. J Neurol 254:879–883CrossRefPubMed Svetel M, Pekmezovic T, Jovic J et al (2007) Spread of primary dystonia in relation to initially affected region. J Neurol 254:879–883CrossRefPubMed
27.
Zurück zum Zitat Weiss EM, Hershey T, Karimi M et al (2006) Relative risk of spread of symptoms among the focal onset primary dystonias. Mov Disord 21:1175–1181CrossRefPubMed Weiss EM, Hershey T, Karimi M et al (2006) Relative risk of spread of symptoms among the focal onset primary dystonias. Mov Disord 21:1175–1181CrossRefPubMed
28.
Zurück zum Zitat Gelb DJ, Yoshimura DM, Olney RK, Lowenstein DH, Aminoff MJ (1991) Change in pattern of muscle activity following botulinum toxin injections for torticollis. Ann Neurol 29:370–376CrossRefPubMed Gelb DJ, Yoshimura DM, Olney RK, Lowenstein DH, Aminoff MJ (1991) Change in pattern of muscle activity following botulinum toxin injections for torticollis. Ann Neurol 29:370–376CrossRefPubMed
30.
Zurück zum Zitat Papapetropoulos S, Tuchman A, Sengun C, Russell A, Mitsi G, Singer C (2008) Anterocollis: clinical features and treatment options. Med Sci Monit 14:CR427–CR430PubMed Papapetropoulos S, Tuchman A, Sengun C, Russell A, Mitsi G, Singer C (2008) Anterocollis: clinical features and treatment options. Med Sci Monit 14:CR427–CR430PubMed
31.
Zurück zum Zitat Jinnah HA, Berardelli A, Comella C et al (2013) The focal dystonias: current views and challenges for future research. Mov Disord 7:926–943CrossRef Jinnah HA, Berardelli A, Comella C et al (2013) The focal dystonias: current views and challenges for future research. Mov Disord 7:926–943CrossRef
32.
Zurück zum Zitat Revuelta GJ, Montilla J, Benatar M et al (2014) An (18)F-FDG PET study of cervical muscle in parkinsonian anterocollis. J Neurol Sci 340:174–177CrossRefPubMedPubMedCentral Revuelta GJ, Montilla J, Benatar M et al (2014) An (18)F-FDG PET study of cervical muscle in parkinsonian anterocollis. J Neurol Sci 340:174–177CrossRefPubMedPubMedCentral
33.
34.
Zurück zum Zitat Bhidayasiri R (2011) Treatment of complex cervical dystonia with botulinum toxin: involvement of deep-cervical muscles may contribute to suboptimal responses. Parkinsonism Relat Disord 17(Suppl 1):S20–S24CrossRefPubMed Bhidayasiri R (2011) Treatment of complex cervical dystonia with botulinum toxin: involvement of deep-cervical muscles may contribute to suboptimal responses. Parkinsonism Relat Disord 17(Suppl 1):S20–S24CrossRefPubMed
35.
Zurück zum Zitat Glass GA, Ku S, Ostrem JL, Heath S, Larson PS (2009) Fluoroscopic, EMG-guided injection of botulinum toxin into the longus colli for the treatment of anterocollis. Parkinsonism Relat Disord 15:610–613CrossRefPubMed Glass GA, Ku S, Ostrem JL, Heath S, Larson PS (2009) Fluoroscopic, EMG-guided injection of botulinum toxin into the longus colli for the treatment of anterocollis. Parkinsonism Relat Disord 15:610–613CrossRefPubMed
36.
Zurück zum Zitat Misra VP, Ehler E, Zakine B, Maisonobe P, Simonetta-Moreau M, Group IIC (2012) Factors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational study. BMJ Open 2(3):e000881CrossRefPubMedPubMedCentral Misra VP, Ehler E, Zakine B, Maisonobe P, Simonetta-Moreau M, Group IIC (2012) Factors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational study. BMJ Open 2(3):e000881CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Flowers JM, Hicklin LA, Marion MH (2011) Anterior and posterior sagittal shift in cervical dystonia: a clinical and electromyographic study, including a new EMG approach of the longus colli muscle. Mov Disord 26:2409–2414CrossRefPubMed Flowers JM, Hicklin LA, Marion MH (2011) Anterior and posterior sagittal shift in cervical dystonia: a clinical and electromyographic study, including a new EMG approach of the longus colli muscle. Mov Disord 26:2409–2414CrossRefPubMed
38.
Zurück zum Zitat Chinnapongse RB, Lew MF, Ferreira JJ, Gullo KL, Nemeth PR, Zhang Y (2012) Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials. Clin Neuropharmacol 35:215–223CrossRefPubMed Chinnapongse RB, Lew MF, Ferreira JJ, Gullo KL, Nemeth PR, Zhang Y (2012) Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials. Clin Neuropharmacol 35:215–223CrossRefPubMed
Metadaten
Titel
Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes
verfasst von
H. A. Jinnah
Emily Goodmann
Ami R. Rosen
Marian Evatt
Alan Freeman
Stewart Factor
Publikationsdatum
25.04.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 6/2016
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-016-8136-x

Weitere Artikel der Ausgabe 6/2016

Journal of Neurology 6/2016 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.